# A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

> **NCT02334306** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 32 (actual)

## Conditions studied

- Primary Sjögren's Syndrome

## Interventions

- **BIOLOGICAL:** AMG 557/MEDI5872
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02334306
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-08
- **Primary completion:** 2018-01-16
- **Final completion:** 2018-08-13
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02334306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02334306, "A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02334306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*